# ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

> **NCT02319005** · PHASE3 · COMPLETED · sponsor: **Alnylam Pharmaceuticals** · enrollment: 206 (actual)

## Conditions studied

- Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
- Amyloidosis, Hereditary
- Amyloid Neuropathies, Familial
- Amyloid Neuropathies
- Amyloidosis, Hereditary, Transthyretin-Related
- Familial Transthyretin Cardiac Amyloidosis

## Interventions

- **DRUG:** Revusiran (ALN-TTRSC)
- **DRUG:** Sterile Normal Saline (0.9% NaCl)

## Key facts

- **NCT ID:** NCT02319005
- **Lead sponsor:** Alnylam Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2017-03-30
- **Final completion:** 2017-03-30
- **Target enrollment:** 206 (ACTUAL)
- **Last updated:** 2018-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02319005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02319005, "ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02319005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*